$54.4 Billion in Deals and Counting: Analyzing Three Quarters of Cell and Gene Therapy Funding
Over 54 BN across funding mechanisms. Private, VC, SPAC and and IPO Over 20Billion
The enormous amount of funding presages confidence in discoveries of future marketable products as well as platforms in cell and gene therapy. With an aggressive third quarter 2021 for funding, it is worthwhile to total and assess where we are. In this section we have gathered and anyalized the deals that have been made this year that have been reported in our issues.
Readers of Cell and Gene Therapy Business Outlook will note there’s been no slowdown in deals activity. There has been an enormous amount of funding for cell and gene therapies in 2021. When M&A is included, this funding has reached $54 BN dollars, according to Cell and Gene Therapy Business Outlook’s analysis. (Even without considering mergers and acquisitions – IPOs, VC, SPAC and private deals exceed $20 billion).
Be Sure to Subscribe to Cell and Gene Therapy Business Outlook for more information.